---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123314"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:29:29.859273+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance

## Summary
- Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).
- Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.
- CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.
- CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.
- CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025.

## SEC filing metadata
- accession: 0000950170-24-123314
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/0000950170-24-123314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/ctmx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123314
- JSON: https://secwatch.observer/filing/0000950170-24-123314.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.